apricus biosciences

Shares of Apricus Biosciences Inc (NASDAQ: APRI) plunged more than 50 percent on Monday after the company disclosed "disappointing" Phase 2b data. Apricus Biosciences stated that a proof-of-concept study of fispemifene in men with secondary hypogonadism and sexual dysfunction failed...

Apricus Biosciences (NASDAQ: APRI), backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that Bassam Damaj, Ph.D., President and Chief Executive Officer, will...